Biomarin Pharmaceutical (BMRN) Revenue (2017 - 2025)
Historic Revenue for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $776.1 million.
- Biomarin Pharmaceutical's Revenue rose 407.55% to $776.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 billion, marking a year-over-year increase of 1239.43%. This contributed to the annual value of $2.9 billion for FY2024, which is 1796.81% up from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Revenue is $776.1 million, which was up 407.55% from $825.4 million recorded in Q2 2025.
- Biomarin Pharmaceutical's Revenue's 5-year high stood at $825.4 million during Q2 2025, with a 5-year trough of $408.7 million in Q3 2021.
- In the last 5 years, Biomarin Pharmaceutical's Revenue had a median value of $595.3 million in 2023 and averaged $608.5 million.
- Its Revenue has fluctuated over the past 5 years, first crashed by 1427.1% in 2021, then soared by 2828.19% in 2024.
- Biomarin Pharmaceutical's Revenue (Quarter) stood at $449.8 million in 2021, then rose by 19.5% to $537.5 million in 2022, then increased by 20.22% to $646.2 million in 2023, then rose by 15.65% to $747.3 million in 2024, then increased by 3.86% to $776.1 million in 2025.
- Its Revenue stands at $776.1 million for Q3 2025, versus $825.4 million for Q2 2025 and $745.1 million for Q1 2025.